Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I dose-escalation study of intravesical TMX-101 in non-muscle-invasive bladder cancer
NL-OMON35119Phase 1Active, not recruiting
- Sponsor
- Telormedix
- Start
- Jun 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TMX-101 in non-muscle-invasive bladder cancer (NMIBC) and transitional cell carcinoma of the bladder (TCC), sponsored by Telormedix. Primary endpoints: Safety profile and dose escalation outcome, Dose-limiting toxicity and 2 more. Started Jun 2010; status: active, not recruiting.
02
Drugs
TMX-101
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)transitional cell carcinoma of the bladder (TCC)
Beyond the preview
Go deeper on NL-OMON35119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON35119.